

Vicente Valero

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11146105/vicente-valero-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

241
papers

23,138
citations

81
h-index

149
g-index

249
ext. papers

26,378
ext. citations

5.8
avg, IF

6.06
L-index

#	Paper	IF	Citations
241	Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	1
240	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.. <i>Npj Breast Cancer</i> , 2022 , 8, 18	7.8	0
239	A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer.. <i>European Journal of Radiology</i> , 2022 , 149, 110220	4.7	0
238	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.. <i>Lancet Oncology</i> , 2021 ,	21.7	16
237	Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. <i>Npj Breast Cancer</i> , 2021 , 7, 28	7.8	1
236	Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula development. <i>Surgery</i> , 2021 , 169, 708-720	3.6	7
235	Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. <i>PLoS ONE</i> , 2021 , 16, e0250057	3.7	1
234	Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. <i>Cancer</i> , 2021 , 127, 2880-2887	6.4	2
233	Update on systemic treatment for newly diagnosed inflammatory breast cancer. <i>Journal of Advanced Research</i> , 2021 , 29, 1-12	13	3
232	Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. <i>European Journal of Cancer</i> , 2021 , 143, 134-146	7.5	16
231	A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. <i>Oncologist</i> , 2021 , 26, e230-e240 ¹	5.7	240 ¹
230	Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). <i>Breast Cancer Research and Treatment</i> , 2021 , 185, 1-12 ^{4.4}	4.4	2
229	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2375-2385	2.2	20
228	What is the best treatment recommendation for HER2+ IBC with residual disease?-a narrative review.. <i>Chinese Clinical Oncology</i> , 2021 , 10, 59	2.3	
227	Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer. <i>Oncologist</i> , 2020 , 25, 749-757	5.7	8
226	Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study. <i>Cancer Prevention Research</i> , 2020 , 13, 795-802	3.2	2
225	Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. <i>Breast Journal</i> , 2020 , 26, 1572-1582	1.2	3

224	Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. <i>Clinical Chemistry</i> , 2020 , 66, 934-945	5.5	3
223	Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. <i>Npj Breast Cancer</i> , 2020 , 6, 11	7.8	1
222	EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream [®] in patients with breast cancer treated with primary systemic therapy. <i>PLoS ONE</i> , 2020 , 15, e0229903	3.7	11
221	An inflammatory imposter: Three cases of Mullerian carcinoma appearing as inflammatory breast cancer. <i>Breast Journal</i> , 2020 , 26, 1022-1024	1.2	
220	Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer. <i>JAMA Surgery</i> , 2020 , 155, e204103	5.4	21
219	Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. <i>European Journal of Radiology</i> , 2020 , 130, 109170	4.7	0
218	Overall survival in older patients with cancer. <i>BMJ Supportive and Palliative Care</i> , 2020 , 10, 25-35	2.2	12
217	Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline Pathogenic Variant. <i>Journal of Clinical Oncology</i> , 2020 , 38, 388-394	2.2	72
216	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2206-2216	2.2	78
215	A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. <i>British Journal of Cancer</i> , 2019 , 120, 1105-1112	8.7	15
214	Elevated serum levels of sialyl Lewis X (sLe) and inflammatory mediators in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 545-556	4.4	10
213	Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 227-234	4.4	8
212	Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919866065	5.4	17
211	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. <i>Breast Cancer Research</i> , 2019 , 21, 78	8.3	75
210	Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. <i>Annals of Surgical Oncology</i> , 2019 , 26, 3071-3079	3.1	10
209	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. <i>Investigational New Drugs</i> , 2019 , 37, 345-351	4.3	20
208	Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. <i>JAMA Oncology</i> , 2019 , 5, 366-375	13.4	17
207	Risk Factors and Mitigation Strategies for Pancreatic Fistula After Distal Pancreatectomy: Analysis of 2026 Resections From the International, Multi-institutional Distal Pancreatectomy Study Group. <i>Annals of Surgery</i> , 2019 , 269, 143-149	7.8	79

206	The Beneficial Effects of Minimizing Blood Loss in Pancreatoduodenectomy. <i>Annals of Surgery</i> , 2019 , 270, 147-157	7.8	32
205	Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018 , 169, 615-623	4.4	7
204	Development of CNS metastases and survival in patients with inflammatory breast cancer. <i>Cancer</i> , 2018 , 124, 2299-2305	6.4	6
203	A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. <i>Investigational New Drugs</i> , 2018 , 36, 299-306	4.3	11
202	Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. <i>Supportive Care in Cancer</i> , 2018 , 26, 1561-1568	3.9	8
201	Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy. <i>Annals of Surgery</i> , 2018 , 267, 608-616	7.8	81
200	A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. <i>Annals of Surgery</i> , 2018 , 267, 946-951	7.8	94
199	Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated?. <i>American Journal of Surgery</i> , 2018 , 215, 693-698	2.7	3
198	Risk factors for falls in older patients with cancer. <i>BMJ Supportive and Palliative Care</i> , 2018 , 8, 34-37	2.2	18
197	Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. <i>Journal of Geriatric Oncology</i> , 2018 , 9, 81-83	3.6	8
196	Pancreatogastrostomy Vs. Pancreatojejunostomy: a Risk-Stratified Analysis of 5316 Pancreatoduodenectomies. <i>Journal of Gastrointestinal Surgery</i> , 2018 , 22, 68-76	3.3	18
195	Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy. <i>Cancer</i> , 2018 , 124, 36-45	6.4	37
194	International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. <i>Journal of Cancer</i> , 2018 , 9, 1437-1447	4.5	45
193	Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. <i>Clinical Breast Cancer</i> , 2018 , 18, e1283-e1288	3	8
192	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2018 , 23, 1300-1309	5.7	28
191	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. <i>JAMA Oncology</i> , 2018 , 4, 1207-1213	13.4	39
190	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 115-126	21.7	203
189	Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. <i>PLoS ONE</i> , 2018 , 13, e0204372	3.7	8

188	A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR- α <i>Investigational New Drugs</i> , 2018 , 36, 1103-1109	4.3	9
187	Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 568-577	4	10
186	Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1049-1060	2.2	288
185	Predictors of left ventricular systolic function recovery in the setting of sinus tachycardia in patients with cancer. <i>Echocardiography</i> , 2017 , 34, 29-36	1.5	
184	Identification of frequent somatic mutations in inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 163, 263-272	4.4	20
183	Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. <i>Cancer</i> , 2017 , 123, 2422-2431	6.4	18
182	Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. <i>JAMA Surgery</i> , 2017 , 152, 665-670	5.4	101
181	A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 777-783	4	17
180	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. <i>JAMA Oncology</i> , 2017 , 3, 509-515	13.4	97
179	Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. <i>Lancet Oncology, The</i> , 2017 , 18, e228-e232	21.7	54
178	Metaplastic Breast Cancer 2017 , 327-337		1
177	Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. <i>Journal of Cancer</i> , 2017 , 8, 2004-2009	4.5	9
176	The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer. <i>Oncology Reviews</i> , 2017 , 11, 324	4.3	19
175	Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. <i>Journal of Oncology Practice</i> , 2017 , 13, 555-556	3.1	3
174	Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. <i>Supportive Care in Cancer</i> , 2017 , 25, 3295-3304	3.9	43
173	Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1360-1372	21.7	263
172	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. <i>Oncotarget</i> , 2017 , 8, 35656-35668	3.3	32
171	The Characterization and Prediction of ISGPF Grade C Fistulas Following Pancreatoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2016 , 20, 262-76	3.3	81

170	HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3518-3528	2.2	92
169	Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 67-77	4.4	14
168	T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3511-3517	2.2	55
167	Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. <i>JAMA Oncology</i> , 2016 , 2, 508-16	13.4	70
166	Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2016 , 23, 1515-21	3.1	53
165	Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. <i>Oncoscience</i> , 2016 , 3, 164-72	0.8	29
164	Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management. <i>Annals of Surgery</i> , 2016 , 263, 153-61	7.8	37
163	Risk-adjusted Outcomes of Clinically Relevant Pancreatic Fistula Following Pancreatoduodenectomy: A Model for Performance Evaluation. <i>Annals of Surgery</i> , 2016 , 264, 344-52	7.8	110
162	High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. <i>Oncologist</i> , 2016 , 21, 21-7	5.7	9
161	A novel risk scoring system reliably predicts readmission after pancreatectomy. <i>Journal of the American College of Surgeons</i> , 2015 , 220, 701-13	4.4	24
160	Circulating tumor cells in newly diagnosed inflammatory breast cancer. <i>Breast Cancer Research</i> , 2015 , 17, 2	8.3	33
159	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 407-16	4.4	50
158	Automated pain intervention for underserved minority women with breast cancer. <i>Cancer</i> , 2015 , 121, 1882-90	6.4	19
157	Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. <i>Clinical Breast Cancer</i> , 2015 , 15, 153-60	3	27
156	Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. <i>JAMA Oncology</i> , 2015 , 1, 1311-8	13.4	52
155	Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	21
154	Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2015 , 153, 417-23	4.4	16
153	Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers. <i>Breast Journal</i> , 2015 , 21, 260-7	1.2	13

152	Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers. <i>Clinical Breast Cancer</i> , 2015 , 15, 37-42	3	5
151	Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. <i>Molecular Oncology</i> , 2015 , 9, 32-43	7.9	63
150	High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. <i>Cancer</i> , 2015 , 121, 3422-7	6.4	50
149	Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. <i>Cancer</i> , 2015 , 121, 4324-32	6.4	22
148	Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015 , 38, 242-7	2.7	22
147	Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. <i>Journal of Cancer</i> , 2015 , 6, 310-8	4.5	14
146	Emerging role of Hpo signaling and YAP in hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2015 , 2, 69-78	5.3	22
145	Tracking early readmission after pancreatectomy to index and nonindex institutions: a more accurate assessment of readmission. <i>JAMA Surgery</i> , 2015 , 150, 152-8	5.4	31
144	Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015 , 15, 325-31	3	15
143	Early hospital readmission for gastrointestinal-related complications predicts long-term mortality after pancreatectomy. <i>American Journal of Surgery</i> , 2015 , 210, 636-42.e1	2.7	8
142	Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 102-10	4	3
141	Sarcopenia adversely impacts postoperative complications following resection or transplantation in patients with primary liver tumors. <i>Journal of Gastrointestinal Surgery</i> , 2015 , 19, 272-81	3.3	139
140	Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. <i>Journal of Oncology Pharmacy Practice</i> , 2014 , 20, 120-9	1.7	12
139	EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014 , 33, 58	12.8	20
138	Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 735-44	2.2	181
137	Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. <i>Cancer</i> , 2014 , 120, 1932-8	6.4	33
136	Carboplatin for early triple-negative breast cancer?. <i>Lancet Oncology, The</i> , 2014 , 15, 676-8	21.7	3
135	Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 392-8	4	105

134	High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. <i>PLoS ONE</i> , 2014 , 9, e83113	3.7	65
133	Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. <i>Journal of Cancer</i> , 2014 , 5, 351-9	4.5	3
132	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. <i>Breast Cancer Research</i> , 2014 , 16, 440	8.3	77
131	Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 3175-84	6.1	26
130	Gene signature-guided dasatinib therapy in metastatic breast cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 5265-71	12.9	20
129	Outcomes of children exposed in utero to chemotherapy for breast cancer. <i>Breast Cancer Research</i> , 2014 , 16, 500	8.3	48
128	Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. <i>Oncotarget</i> , 2014 , 5, 9864-76	3.3	156
127	Detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15225-e15225	2.2	
126	Managing ixabepilone adverse events with dose reduction. <i>Clinical Breast Cancer</i> , 2013 , 13, 1-6	3	4
125	Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2013 , 141, 429-35	4.4	17
124	Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 631-6	4.4	19
123	USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013 , 19, 10-7	2.2	31
122	Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. <i>Clinical Cancer Research</i> , 2013 , 19, 5533-40	12.9	476
121	Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. <i>Surgery</i> , 2012 , 151, 710-6	3.6	89
120	Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. <i>Cancer</i> , 2012 , 118, 326-32	6.4	8
119	Inflammatory breast cancer: what we know and what we need to learn. <i>Oncologist</i> , 2012 , 17, 891-9	5.7	108
118	Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2012 , 12, 264-9	3	67
117	Management of perihilar cholangiocarcinoma in the era of multimodal therapy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012 , 6, 481-95	4.2	41

116	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 333-43	4.4	94
115	Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. <i>Cancer</i> , 2012 , 118, 2385-93	6.4	39
114	Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 1067-75	4.4	82
113	Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. <i>Journal of Clinical Oncology</i> , 2012 , 30, 729-34	2.2	174
112	Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2526-34	6.1	165
111	Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. <i>Clinical Cancer Research</i> , 2012 , 18, 3478-86	12.9	89
110	Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 930-5	2.2	29
109	Carcinosarcoma of the Breast 2012 , 257-269		
108	Clinical Aspect of Inflammatory Breast Cancer: Diagnosis, Criteria, Controversy 2012 , 11-19		1
107	Adjuvant trastuzumab in HER2-positive breast cancer. <i>New England Journal of Medicine</i> , 2011 , 365, 1273-82	39.2	1788
106	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. <i>Breast Cancer Research</i> , 2011 , 13, R67	8.3	161
105	Age and associated fibrocystic changes are prognostically significant in patients with small node-negative (T1a,bN0) invasive breast cancer. <i>Breast Journal</i> , 2011 , 17, 462-9	1.2	1
104	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 785-95	4.4	54
103	Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. <i>Cancer</i> , 2011 , 117, 1819-26	6.4	102
102	Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. <i>International Journal of Cancer</i> , 2011 , 129, 417-23	7.5	81
101	Ixabepilone for the treatment of breast cancer. <i>Annals of Medicine</i> , 2011 , 43, 477-86	1.5	9
100	Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3739-46	2.2	125
99	Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. <i>Journal of Clinical Oncology</i> , 2011 , 29, 148-56	2.2	188

98	A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1873-81	27.4	414
97	Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2628-34	2.2	102
96	Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. <i>Oncologist</i> , 2011 , 16, 1675-83	5.7	70
95	RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4286-93	2.2	322
94	Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. <i>Cancer Research</i> , 2010 , 70, 8852-62	10.1	49
93	Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 5351-61	12.9	153
92	Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4316-23	2.2	163
91	Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. <i>Lancet Oncology</i> , 2010 , 11, 358-65	21.7	97
90	Genomic index of sensitivity to endocrine therapy for breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4111-9	2.2	203
89	Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. <i>Breast Cancer Research</i> , 2010 , 12, R5	8.3	136
88	Sentinel lymph node dissection is technically feasible in older breast cancer patients. <i>Clinical Breast Cancer</i> , 2010 , 10, 477-82	3	4
87	Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4111-9	6.4	10
86	Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. <i>Cancer</i> , 2010 , 116, 4168-77	6.4	32
85	Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. <i>Breast Journal</i> , 2010 , 16, 327-30	1.2	31
84	Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. <i>Cancer Research</i> , 2009 , 69, 4116-24	10.1	674
83	Breast cancer metastasis: challenges and opportunities. <i>Cancer Research</i> , 2009 , 69, 4951-3	10.1	152
82	High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5700-6	2.2	338
81	Genomic grade index is associated with response to chemotherapy in patients with breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3185-91	2.2	153

80	Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 3654-62	12.9	109
79	Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. <i>Cancer</i> , 2009 , 115, 1605-12	6.4	23
78	Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009 , 135, 141-8	4.9	10
77	Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3303-11	2.2	126
76	Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. <i>Clinical Breast Cancer</i> , 2008 , 8, 516-23	10.1	10
75	PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. <i>Breast Cancer Research</i> , 2008 , 10, R27	8.3	43
74	An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. <i>Cancer Research</i> , 2008 , 68, 6084-91	10.1	806
73	Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4282-8	2.2	435
72	Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 7909-16	12.9	44
71	A management algorithm and practical oncoplastic surgical techniques for repairing partial mastectomy defects. <i>Plastic and Reconstructive Surgery</i> , 2008 , 122, 1631-1647	2.7	112
70	Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. <i>Cancer</i> , 2008 , 112, 1455-61	6.4	87
69	Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?. <i>Cancer</i> , 2008 , 113, 2422-30	6.4	137
68	Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. <i>Clinical Breast Cancer</i> , 2007 , 7, 34-42	3	115
67	Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. <i>Cancer</i> , 2007 , 110, 1436-44	6.4	153
66	Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 67, 490-6	4	22
65	Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2650-5	2.2	215
64	Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4952-60	2.2	214
63	Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. <i>Clinical Cancer Research</i> , 2007 , 13, 228-33	12.9	379

62	Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4414-22	2.2	914
61	Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. <i>Lancet Oncology, The</i> , 2007 , 8, 203-11	21.7	157
60	CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. <i>Breast Cancer Research</i> , 2007 , 9, R87	8.3	23
59	Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. <i>Cancer</i> , 2006 , 106, 1000-6	6.4	43
58	Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. <i>Cancer</i> , 2006 , 106, 2327-36	6.4	23
57	Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2113-22	2.2	90
56	Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1037-44	2.2	453
55	Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4107-15	2.2	295
54	Neoadjuvant Therapy of Breast Cancer. <i>American Journal of Cancer</i> , 2006 , 5, 411-425		1
53	Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4236-44	2.2	556
52	Docetaxel for treatment of solid tumours: a systematic review of clinical data. <i>Lancet Oncology, The</i> , 2005 , 6, 229-39	21.7	217
51	Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 1477-91	4	30
50	Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 62, 351-7	4	98
49	Squamous cell carcinoma of the breast. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7827-35	2.2	127
48	Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7820-6	2.2	551
47	Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5983-92	2.2	345
46	Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. <i>Journal of Clinical Oncology</i> , 2005 , 23, 41-8	2.2	292
45	Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9304-11	2.2	311

44	Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8331-9	2.2	218
43	Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4691-9	2.2	218
42	Pain education for underserved minority cancer patients: a randomized controlled trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4918-25	2.2	80
41	Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. <i>Annals of Surgical Oncology</i> , 2004 , 11, 854-60	3.1	56
40	Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. <i>Cancer</i> , 2004 , 101, 1508-13	6.4	32
39	T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 58, 133-45	4	57
38	Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2003 , 9, 33-41	2.2	104
37	A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. <i>Cancer</i> , 2003 , 97, 2716-23	6.4	13
36	Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. <i>Cancer</i> , 2003 , 98, 504-7	6.4	82
35	A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. <i>Cancer</i> , 2003 , 98, 900-7	6.4	24
34	International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2600-8	2.2	276
33	Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. <i>Clinical Cancer Research</i> , 2003 , 9, 2406-15	12.9	131
32	Cancer pain management among underserved minority outpatients: perceived needs and barriers to optimal control. <i>Cancer</i> , 2002 , 94, 2295-304	6.4	186
31	Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 53, 1225-33	4	50
30	Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1800-8	2.2	473
29	Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2002 , 8, 461-8	2.2	75
28	Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. <i>Clinical Breast Cancer</i> , 2002 , 3 Suppl 2, S63-8	3	40
27	Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. <i>Cancer Investigation</i> , 2002 , 20, 29-37	2.1	12

26	Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. <i>Clinical Cancer Research</i> , 2002 , 8, 1073-9	12.9	110
25	Primary chemotherapy with docetaxel for the management of breast cancer. <i>Oncology</i> , 2002 , 16, 35-43	1.8	3
24	Primary soft tissue sarcoma of the breast. <i>Current Treatment Options in Oncology</i> , 2001 , 2, 169-76	5.4	19
23	Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. <i>Cancer</i> , 2001 , 91, 664-671	6.4	8
22	Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. <i>Cancer</i> , 2001 , 92, 1775-82	6.4	63
21	Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. <i>Cancer</i> , 2001 , 92, 2523-8	6.4	129
20	Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. <i>Cancer Investigation</i> , 2001 , 19, 459-66	2.1	7
19	Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. <i>Oncologist</i> , 2001 , 6, 133-46	4.6	131
18	Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. <i>Journal of Clinical Oncology</i> , 2001 , 19, 628-33	2.2	163
17	Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1716-22	2.2	54
16	Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2587-95	2.2	474
15	Female patients with breast carcinoma age 30 years and younger have a poor prognosis 2001 , 92, 2523		1
14	Minority cancer patients and their providers 2000 , 88, 1929-1938		201
13	Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. <i>Cancer</i> , 2000 , 88, 2054-60	6.4	28
12	Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. <i>Cancer</i> , 2000 , 89, 2195-201	6.4	16
11	Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 225-33	9.7	141
10	Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. <i>Lancet, The</i> , 2000 , 355, 281-3	4.0	100
9	Risks and benefits of taxanes in breast and ovarian cancer. <i>Drug Safety</i> , 2000 , 23, 401-28	5.1	84

8	Minority cancer patients and their providers 2000 , 88, 1929		30
7	Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1425-34	2.2	75
6	Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3412-7	2.2	207
5	Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. <i>Breast Cancer Research and Treatment</i> , 1999 , 54, 225-33	4.4	10
4	Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. <i>Cancer</i> , 1999 , 86, 1251-7	6.4	20
3	Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. <i>Cancer</i> , 1998 , 82, 965-9	6.4	37
2	Paclitaxel-induced pancreatitis: a case report. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 91-3	9.7	15
1	Locally Advanced Breast Cancer. <i>Oncologist</i> , 1996 , 1, 8-17	5.7	53